Fiber foods

BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M in Series A Funding to Develop Leading Products

DAVIS, Calif.–(BUSINESS WIRE)–BCD Biosciences, a biotechnology company that creates precision prebiotics from natural fibers, today announced that it has completed an oversubscribed $12 million Series A funding round led by Acre Venture Partners. Existing investors, Seventure Partners and iSelect Fund, have stepped up their commitments for the round and new investors, Collaborative Fund and Skyviews Life Science, have joined.

The funding will be used to secure regulatory approvals for lead products, increase production capabilities, expand the product portfolio, and continue to develop the prediction and screening platform. CEO Steve Watkins said, “We are extremely pleased to have secured the funding necessary to convert our promising prebiotics into high-value products and commercial opportunities. I am also delighted that our ability to deliver during our seed phase in building our prebiotic library, screening platform and pipeline has given our investors such confidence.

“We are delighted to have worked with Steve and the entire BCD team. Their unique platform and precision prebiotics will be key to advancing public health, while helping to reduce waste in our food systems. As this space continues to evolve, BCD will play a critical role, not only in functional foods and medical nutrition, but also in therapeutics,” said Gareth Asten, Managing Partner at Acre Venture Partners.


BCD Bioscience was founded in 2019 as a spin-out from UC Davis, to harness the functional and health benefits of oligosaccharides obtained from natural sources, including food waste. The company has proven that its breakthrough technology can produce precision prebiotics from most natural fiber sources and has validated its scientific platform for the rapid screening of prebiotics for precise functional properties, including impact on biotherapies living organisms, microbial composition and function, and active (postbiotic) metabolites. The platform is also able to provide in-depth insights into carbohydrate structure and the use of prebiotics by bacteria. Commercial applications include food, nutritional products and therapeutic products.